[The Role of Nurses in Chimeric Antigen Receptor T-Cell Therapy]

Chimeric antigen receptor T-cell (CAR-T) therapy represents a significant breakthrough in contemporary oncology. By engineering patients' autologous T cells to precisely target tumor cells, CAR-T offers new treatment opportunities for individuals with refractory hematologic malignancies. However, the therapeutic process is complex and accompanied by high-risk adverse effects, including cytokine release syndrome, immune effector cell-associated neurotoxicity, and infections, all of which pose major challenges to clinical nursing. Nurses play a pivotal role across the CAR-T care continuum in terms of providing pre-treatment education and health assessments, vigilant monitoring and complication management during therapy, and post-discharge follow-up and self-care guidance. Clinical nurses must demonstrate acute clinical sensitivity to identify the early warning signs of adverse events and collaborate closely with multidisciplinary teams to ensure timely intervention. Moreover, nurses serve as essential communicators between patients and families, coordinating interdisciplinary care to ensure treatment plans are implemented accurately as well as providing psychological support to reduce anxiety and uncertainty. In the post-discharge phase, ongoing education and follow-up further empower patients and caregivers to strengthen self-management skills, thereby enhancing treatment safety and quality of life. In conclusion, the success of CAR-T therapy depends not only on advances in medical technology but also on the comprehensive professional care and humanistic support delivered by nurses.